Kiniksa Pharmaceuticals International Plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
54.7%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$993.7Mnext fiscal year
FY EPS (est.)
$1.16next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 30 Oct 2026 |
Monitoring Framework
Key Performance Indicators
ARCALYST Net Product Revenue Quarterly214.3MTarget: $930 million to $945 million (Full-Year 2026 Guidance)
Number of Unique Prescribers for ARCALYST Quarterly4.6KTarget: Continued expansion of physician adoption
Cash, Cash Equivalents, and Short-Term Investments Quarterly468.1MTarget: Maintain positive annual operating cash flow
Watch Items
- KPL-387 Phase 2 Clinical Trial DataTrigger: Release of Phase 2 dose-focusing data in recurrent pericarditisAction: Evaluate efficacy, safety, and PK/PD profile to finalize dose selection and initiate Phase 3 pivotal trial by year-end 2026.
- KPL-1161 Phase 1 Trial InitiationTrigger: First-in-human clinical trial initiationAction: Begin Phase 1 trial by the end of 2026 to evaluate safety and tolerability of the quarterly subcutaneous dosing profile.
- ARCALYST Market PenetrationTrigger: Penetration rate of the 14,000 multiple-recurrence patient population in the U.S.Action: Monitor expansion beyond the ~18% penetration level achieved at year-end 2025 through targeted marketing and physician education.
Research as of 19 Jun 2026